Literature DB >> 28323960

FGF23 Is Not Associated With Age-Related Changes in Phosphate, but Enhances Renal Calcium Reabsorption in Girls.

Deborah M Mitchell1,2, Harald Jüppner1,3, Sherri-Ann M Burnett-Bowie1.   

Abstract

Context: Fibroblast growth factor (FGF)23 is a critical determinant of phosphate homeostasis. The role of FGF23, however, in regulating physiologic changes in serum phosphate and renal phosphate handling across childhood is not well described. In addition, animal models have suggested a role for FGF23 in regulating renal calcium excretion. Objective: To assess changes in FGF23 concentrations across childhood in relation to changes in mineral ions and hormones of mineral ion homeostasis. Design: This was a cross-sectional study. Setting: The study was conducted at a Clinical Research Center at a tertiary care hospital. Patients or Other Participants: Ninety healthy girls ages 9 to 18 years were recruited from the surrounding community. Main Outcome Measures: The associations of intact and C-terminal FGF23 concentrations with measures of mineral ion homeostasis were determined by univariable and multivariable linear regression.
Results: Serum phosphate and renal phosphate excretion varied with age, as expected (R = -0.49, P < 0.001 and R = -0.48, P < 0.001, respectively). Neither intact nor C-terminal FGF23 varied with age, and FGF23 was not correlated with serum or urinary phosphate. Intact FGF23 was positively correlated with serum calcium (R = 0.39, P < 0.001) and negatively correlated with urinary calcium/creatinine ratio (R = -0.27, P = 0.011). Conclusions: The changes in serum and urinary phosphate handling across childhood do not appear to be determined by alterations in FGF23 concentrations. These data may point to a role for FGF23 in calcium regulation in human physiology.
Copyright © 2017 by the Endocrine Society

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28323960      PMCID: PMC5460726          DOI: 10.1210/jc.2016-4038

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  52 in total

1.  Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism.

Authors:  Takashi Shimada; Yuji Yamazaki; Motoo Takahashi; Hisashi Hasegawa; Itaru Urakawa; Takeshi Oshima; Kaori Ono; Makoto Kakitani; Kazuma Tomizuka; Toshiro Fujita; Seiji Fukumoto; Takeyoshi Yamashita
Journal:  Am J Physiol Renal Physiol       Date:  2005-07-05

2.  Age- and sex-specific dynamics in 22 hematologic and biochemical analytes from birth to adolescence.

Authors:  Jakob Zierk; Farhad Arzideh; Tobias Rechenauer; Rainer Haeckel; Wolfgang Rascher; Markus Metzler; Manfred Rauh
Journal:  Clin Chem       Date:  2015-05-12       Impact factor: 8.327

3.  Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo.

Authors:  Hitoshi Saito; Akira Maeda; Shu-Ichi Ohtomo; Michinori Hirata; Kenichiro Kusano; Shigeaki Kato; Etsuro Ogata; Hiroko Segawa; Ken-Ichi Miyamoto; Naoshi Fukushima
Journal:  J Biol Chem       Date:  2004-11-05       Impact factor: 5.157

4.  Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23.

Authors: 
Journal:  Nat Genet       Date:  2000-11       Impact factor: 38.330

5.  FGF-23 is elevated by chronic hyperphosphatemia.

Authors:  A Gupta; K Winer; M J Econs; S J Marx; M T Collins
Journal:  J Clin Endocrinol Metab       Date:  2004-09       Impact factor: 5.958

6.  Association of serum fibroblast growth factor 23 (FGF23) and incident fractures in older men: the Osteoporotic Fractures in Men (MrOS) study.

Authors:  Nancy E Lane; Neeta Parimi; Maripat Corr; Wei Yao; Jane A Cauley; Carrie M Nielson; Joseph H Ix; Deborah Kado; Eric Orwoll
Journal:  J Bone Miner Res       Date:  2013-11       Impact factor: 6.741

7.  Demographic, dietary, and urinary factors and 24-h urinary calcium excretion.

Authors:  Eric N Taylor; Gary C Curhan
Journal:  Clin J Am Soc Nephrol       Date:  2009-10-09       Impact factor: 8.237

8.  Calcium deficiency reduces circulating levels of FGF23.

Authors:  María E Rodriguez-Ortiz; Ignacio Lopez; Juan R Muñoz-Castañeda; Julio M Martinez-Moreno; Alan Peralta Ramírez; Carmen Pineda; Antonio Canalejo; Philippe Jaeger; Escolastico Aguilera-Tejero; Mariano Rodriguez; Arnold Felsenfeld; Yolanda Almaden
Journal:  J Am Soc Nephrol       Date:  2012-05-10       Impact factor: 10.121

9.  Height adjustment in assessing dual energy x-ray absorptiometry measurements of bone mass and density in children.

Authors:  Babette S Zemel; Mary B Leonard; Andrea Kelly; Joan M Lappe; Vicente Gilsanz; Sharon Oberfield; Soroosh Mahboubi; John A Shepherd; Thomas N Hangartner; Margaret M Frederick; Karen K Winer; Heidi J Kalkwarf
Journal:  J Clin Endocrinol Metab       Date:  2010-01-26       Impact factor: 5.958

10.  Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis.

Authors:  Tobias Larsson; Richard Marsell; Ernestina Schipani; Claes Ohlsson; Osten Ljunggren; Harriet S Tenenhouse; Harald Jüppner; Kenneth B Jonsson
Journal:  Endocrinology       Date:  2004-02-26       Impact factor: 4.736

View more
  9 in total

Review 1.  Biology of Fibroblast Growth Factor 23: From Physiology to Pathology.

Authors:  Marie Courbebaisse; Beate Lanske
Journal:  Cold Spring Harb Perspect Med       Date:  2018-05-01       Impact factor: 6.915

2.  Calcitriol and FGF-23, but neither PTH nor sclerostin, are associated with calciuria in CKD.

Authors:  J Ramalho; E M Petrillo; A P M Takeichi; R M A Moyses; S M Titan
Journal:  Int Urol Nephrol       Date:  2019-07-31       Impact factor: 2.370

3.  Trabecular Bone Morphology Correlates With Skeletal Maturity and Body Composition in Healthy Adolescent Girls.

Authors:  Deborah M Mitchell; Signe Caksa; Amy Yuan; Mary L Bouxsein; Madhusmita Misra; Sherri-Ann M Burnett-Bowie
Journal:  J Clin Endocrinol Metab       Date:  2018-01-01       Impact factor: 5.958

Review 4.  Interdisciplinary management of FGF23-related phosphate wasting syndromes: a Consensus Statement on the evaluation, diagnosis and care of patients with X-linked hypophosphataemia.

Authors:  Andrea Trombetti; Nasser Al-Daghri; Maria Luisa Brandi; Jorge B Cannata-Andía; Etienne Cavalier; Manju Chandran; Catherine Chaussain; Lucia Cipullo; Cyrus Cooper; Dieter Haffner; Pol Harvengt; Nicholas C Harvey; Muhammad Kassim Javaid; Famida Jiwa; John A Kanis; Andrea Laslop; Michaël R Laurent; Agnès Linglart; Andréa Marques; Gabriel T Mindler; Salvatore Minisola; María Concepción Prieto Yerro; Mario Miguel Rosa; Lothar Seefried; Mila Vlaskovska; María Belén Zanchetta; René Rizzoli
Journal:  Nat Rev Endocrinol       Date:  2022-04-28       Impact factor: 43.330

5.  Extra-Large Gα Protein (XLαs) Deficiency Causes Severe Adenine-Induced Renal Injury with Massive FGF23 Elevation.

Authors:  Julia Matthias; Qiuxia Cui; Lauren T Shumate; Antonius Plagge; Qing He; Murat Bastepe
Journal:  Endocrinology       Date:  2020-01-01       Impact factor: 4.736

Review 6.  FGF23 and its role in X-linked hypophosphatemia-related morbidity.

Authors:  Signe Sparre Beck-Nielsen; Zulf Mughal; Dieter Haffner; Ola Nilsson; Elena Levtchenko; Gema Ariceta; Carmen de Lucas Collantes; Dirk Schnabel; Ravi Jandhyala; Outi Mäkitie
Journal:  Orphanet J Rare Dis       Date:  2019-02-26       Impact factor: 4.123

7.  Diagnostic value of fibroblast growth factor 23 for abdominal aortic calcification in Indonesian hemodialysis patients.

Authors:  Riri Andri Muzasti; Netty Delvrita Lubis
Journal:  Tzu Chi Med J       Date:  2021-03-09

8.  Serum intact fibroblast growth factor 23 in healthy paediatric population.

Authors:  Malgorzata Stanczyk; Slawomir Chrul; Krystyna Wyka; Marcin Tkaczyk
Journal:  Open Med (Wars)       Date:  2021-07-06

9.  Under-recognized Hypoparathyroidism in Thalassemia

Authors:  Hataitip Tangngam; Pat Mahachoklertwattana; Preamrudee Poomthavorn; Ampaiwan Chuansumrit; Nongnuch Sirachainan; La-or Chailurkit; Patcharin Khlairit
Journal:  J Clin Res Pediatr Endocrinol       Date:  2018-05-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.